From: Evidence-based medicine and clinical fluorodeoxyglucose PET/MRI in oncology
Study | Population & setting | Reference standard | Outcome [95Â % CI] | |||
---|---|---|---|---|---|---|
PET-CT | WB-MRI | |||||
Sensitivity | PPV | Sensitivity | PPV | |||
Donati et al. (2010) [21] | Various (n = 37, Colorectal Cancer: n = 20) | Histology or follow-up | 76 [64–86] % | 93 [82–98] % | 91 [80–96] % | 100 [93–100] % |
Schmidt et al. (2009) [16] | Recurrent Colorectal Cancer | Follow-up (mean 11 months) | 86 [65–95] % | 100 [82–100] % | 100 [85–100] % | 100 [85–100] % |
Self-controlled study (n = 24) | ||||||
Pfannenberg et al. (2007) [15] | Recurrent melanoma | Histology or 8 months follow-up | 94 [81–98] % | 100 [90–100] % | 100 [90–100] % | 100 [90–100] % |
Self-controlled study (n = 64) | ||||||
Laurent et al. (2010) [19] | Recurrent melanoma | Histology or 6 months follow-up | 50 [15–85] % | 100 [51–100] % | 100 [51–100] % | 100 [51–100] % |
Self-controlled study (n = 35) | ||||||
Jouvet et al. (2014) [20] | Recurrent melanoma | Histology or ≥6 months follow-up | 100 [76–100] % | 100 k[76–100] % | 100 [76–100] % | 92 [67–99] % |
Self-controlled study (n = 37) | ||||||
Weighted averages | (n = 90) |  | 84 [77–90] % | 97 [92–99] % | 96 [91–98] % | 99 [96–100] % |